L’Oréal has announced a strategic research partnership with TRU DIAGNOSTIC, a company specializing in epigenomics. The collaboration’s main objective is to explore the connection between beauty indicators and changes in epigenomic markers, seeking significant advancements in the field of longevity and long-term skin and hair health.
The partnership will focus on innovative studies to unravel the intricate relationship between epigenetics (the study of how behaviors and environment can cause changes that affect the way genes work) and beauty. The expectation is that this union of expertise will lead to the development of advanced products that promote not only aesthetics but also lasting skin and hair health.
This pioneering collaboration signals a shift towards a deeper, more biological understanding of beauty and aging. By delving into epigenomic markers, L’Oréal and TRU DIAGNOSTIC aim to move beyond surface-level treatments, potentially unlocking new pathways to influence skin and hair health from a foundational, cellular level. The insights gained could redefine how personalized beauty solutions are developed, offering more targeted and effective approaches to maintaining youthful vitality over time.
Guive Balooch, Head of Open Innovation and Augmented Beauty at L’Oréal, stated that the partnership represents an important milestone, combining L’Oréal’s deep understanding of beauty biology with TRU DIAGNOSTIC’s specialization in epigenomics. Matthew Dawson, CEO of TRU DIAGNOSTIC, also expressed enthusiasm for the collaboration, highlighting the potential of epigenomics to revolutionize the understanding of beauty at a biological level.
Source: L’Oréal
